文献速递肝病

基于microRNA的预后模型优于醋氨酚诱导急性肝衰竭的标准预后模型

A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure.
PubMed 文献 · J Hepatol · 2021-04-12

该研究利用美国ALF研究组194例醋氨酚诱导急性肝衰竭患者血清,在早期(第1-2天)和晚期(第3-5天)检测22种microRNA并构建预后模型。早期模型AUC为0.78,晚期模型AUC为0.83,联合MELD评分和升压药使用后均优于King's College标准;早期模型联合临床参数还优于ALF研究组预后指数和MELD评分。

要点

  • 再生相关microRNA特征联合临床参数可预测醋氨酚诱导ALF的不良预后。
  • 早期模型AUC 0.78,晚期模型AUC 0.83,均优于King's College标准。
  • 联合MELD评分和升压药使用可增强模型性能。

核心结论

  • 再生相关microRNA特征联合常规临床参数可优于现有预后模型,识别可能受益于移植的差预后患者。

研究设计与样本

  • 嵌套病例对照研究,使用美国ALF研究组登记(1998-2014)的194例醋氨酚诱导ALF患者血清样本,在早期(第1-2天)和晚期(第3-5天)检测22种microRNA的qPCR panel。

主要发现

  • 单个microRNA单独使用时预后价值有限。
  • 早期时间点模型AUC=0.78(95%CI 0.71-0.84),包含与肝再生相关的microRNA特征。
  • 晚期时间点模型AUC=0.83(95%CI 0.76-0.89),包含与细胞死亡相关的microRNA特征。
  • 两模型联合MELD评分和升压药使用后性能增强,且均优于King's College标准。
  • 早期模型联合临床参数优于ALF研究组预后指数和MELD评分。

关键数值与推荐

  • 早期模型AUC=0.78(95%CI 0.71-0.84)。
  • 晚期模型AUC=0.83(95%CI 0.76-0.89)。
  • 模型比较采用DeLong方法。

临床怎么用

  • 对于醋氨酚诱导ALF患者,可考虑使用基于microRNA的预后模型联合MELD评分和升压药使用来识别差预后患者,辅助移植决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Acetaminophen (APAP)-induced acute liver failure (ALF) remains the most common cause of ALF in the Western world. Conventional prognostic models, utilising markers of liver injury and organ failure, lack sensitivity for mortality prediction. We previously identified a microRNA signature that is associated with successful regeneration post-auxiliary liver transplant and with recovery from APAP-ALF. Herein, we aimed to use this microRNA signature to develop outcome prediction models for APAP-ALF. METHODS: We undertook a nested, case-control study using serum samples from 194 patients with APAP-ALF enrolled in the US ALF Study Group registry (1998-2014) at early (day 1-2) and late (day 3-5) time-points. A microRNA qPCR panel of 22 microRNAs was utilised to assess microRNA expression at both time-points. Multiple logistic regression was used to develop models which were compared to conventional prognostic models using the DeLong method. RESULTS: Individual microRNAs confer limited prognostic value when utilised in isolation. However, incorporating them within microRNA-based outcome prediction models increases their clinical utility. Our early time-point model (AUC = 0.78, 95% CI 0.71-0.84) contained a microRNA signature associated with liver regeneration and our late time-point model (AUC = 0.83, 95% CI 0.76-0.89) contained a microRNA signature associated with cell-death. Both models were enhanced when combined with model for end-stage liver disease (MELD) score and vasopressor use and both outperformed the King's College criteria. The early time-point model combined with clinical parameters outperformed the ALF Study Group prognostic index and the MELD score. CONCLUSIONS: Our findings demonstrate that a regeneration-linked microRNA signature combined with readily available clinical parameters can outperform existing prognostic models for ALF in identifying patients with poor prognosis who may benefit from transplantation. LAY SUMMARY: While acute liver failure can be reversible, some patients will die without a liver transplant. We show that blood test markers that measure the potential for liver recovery may help improve identification of patients unlikely to survive acute liver failure who may benefit from a liver transplant.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Tavabie OD, Karvellas CJ, Salehi S, et al. A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure. J Hepatol. 2021. PMID: 33857547. doi:10.1016/j.jhep.2021.03.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。